Episode Details
Back to Episodes
Daily Roundup | Amylyx Avexitide Wins Phase 3: 55% Fewer Hypoglycemic Events, Filing at Stake
Published 1 month ago
Description
Amylyx's avexitide cut serious hypoglycemic events 55% in Phase 3, sending shares up 54% to a three-year high - on a drug bought for $35 million out of bankruptcy. We break down BioMarin's $275 million Alesta acquisition and oral hypophosphatasia candidate ALE1, Leo Pharma's $435 million dersimelagon license from Tanabe in erythropoietic protoporphyria, EyePoint's 67% Duravyu crash in wet AMD against Eylea, and Moderna's mFlusiva mRNA flu vaccine approval. Visit us at thepharmacloseout.com.